APC-targeted (dna) vaccine delivery platforms: Nanoparticle aided

Pirouz Daftarian, Paolo Serafini, Victor L Perez Quinones, Vance Lemmon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Only a small fraction of any administered drug, including a vaccine, reaches its intended target tissue or cells. Homing vaccines to antigen-presenting cells (APC), where they can do their magic, has been the focus of attention for several decades. Since they are equipped with proper co-stimulatory signals, only professional APC are able to correctly process antigens and stimulate T and B cells to mount specific immune responses. With advances in the fields of modern immunology and nanotechnology, the new vaccine delivery platforms are emerging. APC-targeted vaccine delivery is required to elicit protective immunity, to reduce manufacturing costs, to minimize unanticipated effects of vaccines caused by off-target effects (thus reducing immunosuppressive mechanisms and toxicity), and to dramatically increase immunization efficacy. Indeed, in vivo targeting of APCs may represent the best hope for the generation of strategies leading to a personalized immunization without the need of expensive and complex ex vivo manipulation of patients’ PBMCs. Here, we will review and compare novel approaches on nanoparticle-based-targeted vaccine platforms, evaluating their molecular mechanisms of action, their translation ability, their efficacy, and their cost.

Original languageEnglish (US)
Title of host publicationMolecular Vaccines: From Prophylaxis to Therapy - Volume 2
PublisherSpringer International Publishing
Pages753-766
Number of pages14
ISBN (Print)9783319009780, 9783319009773
DOIs
StatePublished - Jan 1 2014

Fingerprint

Antigen-Presenting Cells
Nanoparticles
Vaccines
Heterologous Immunity
Immunization
Costs and Cost Analysis
Magic
Nanotechnology
Immunosuppressive Agents
Allergy and Immunology
Immunity
B-Lymphocytes
T-Lymphocytes
Antigens
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Daftarian, P., Serafini, P., Perez Quinones, V. L., & Lemmon, V. (2014). APC-targeted (dna) vaccine delivery platforms: Nanoparticle aided. In Molecular Vaccines: From Prophylaxis to Therapy - Volume 2 (pp. 753-766). Springer International Publishing. https://doi.org/10.1007/978-3-319-00978-0_21

APC-targeted (dna) vaccine delivery platforms : Nanoparticle aided. / Daftarian, Pirouz; Serafini, Paolo; Perez Quinones, Victor L; Lemmon, Vance.

Molecular Vaccines: From Prophylaxis to Therapy - Volume 2. Springer International Publishing, 2014. p. 753-766.

Research output: Chapter in Book/Report/Conference proceedingChapter

Daftarian, P, Serafini, P, Perez Quinones, VL & Lemmon, V 2014, APC-targeted (dna) vaccine delivery platforms: Nanoparticle aided. in Molecular Vaccines: From Prophylaxis to Therapy - Volume 2. Springer International Publishing, pp. 753-766. https://doi.org/10.1007/978-3-319-00978-0_21
Daftarian P, Serafini P, Perez Quinones VL, Lemmon V. APC-targeted (dna) vaccine delivery platforms: Nanoparticle aided. In Molecular Vaccines: From Prophylaxis to Therapy - Volume 2. Springer International Publishing. 2014. p. 753-766 https://doi.org/10.1007/978-3-319-00978-0_21
Daftarian, Pirouz ; Serafini, Paolo ; Perez Quinones, Victor L ; Lemmon, Vance. / APC-targeted (dna) vaccine delivery platforms : Nanoparticle aided. Molecular Vaccines: From Prophylaxis to Therapy - Volume 2. Springer International Publishing, 2014. pp. 753-766
@inbook{fcb013f0b4a346eeb5bc6382b4472415,
title = "APC-targeted (dna) vaccine delivery platforms: Nanoparticle aided",
abstract = "Only a small fraction of any administered drug, including a vaccine, reaches its intended target tissue or cells. Homing vaccines to antigen-presenting cells (APC), where they can do their magic, has been the focus of attention for several decades. Since they are equipped with proper co-stimulatory signals, only professional APC are able to correctly process antigens and stimulate T and B cells to mount specific immune responses. With advances in the fields of modern immunology and nanotechnology, the new vaccine delivery platforms are emerging. APC-targeted vaccine delivery is required to elicit protective immunity, to reduce manufacturing costs, to minimize unanticipated effects of vaccines caused by off-target effects (thus reducing immunosuppressive mechanisms and toxicity), and to dramatically increase immunization efficacy. Indeed, in vivo targeting of APCs may represent the best hope for the generation of strategies leading to a personalized immunization without the need of expensive and complex ex vivo manipulation of patients’ PBMCs. Here, we will review and compare novel approaches on nanoparticle-based-targeted vaccine platforms, evaluating their molecular mechanisms of action, their translation ability, their efficacy, and their cost.",
author = "Pirouz Daftarian and Paolo Serafini and {Perez Quinones}, {Victor L} and Vance Lemmon",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-319-00978-0_21",
language = "English (US)",
isbn = "9783319009780",
pages = "753--766",
booktitle = "Molecular Vaccines: From Prophylaxis to Therapy - Volume 2",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - APC-targeted (dna) vaccine delivery platforms

T2 - Nanoparticle aided

AU - Daftarian, Pirouz

AU - Serafini, Paolo

AU - Perez Quinones, Victor L

AU - Lemmon, Vance

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Only a small fraction of any administered drug, including a vaccine, reaches its intended target tissue or cells. Homing vaccines to antigen-presenting cells (APC), where they can do their magic, has been the focus of attention for several decades. Since they are equipped with proper co-stimulatory signals, only professional APC are able to correctly process antigens and stimulate T and B cells to mount specific immune responses. With advances in the fields of modern immunology and nanotechnology, the new vaccine delivery platforms are emerging. APC-targeted vaccine delivery is required to elicit protective immunity, to reduce manufacturing costs, to minimize unanticipated effects of vaccines caused by off-target effects (thus reducing immunosuppressive mechanisms and toxicity), and to dramatically increase immunization efficacy. Indeed, in vivo targeting of APCs may represent the best hope for the generation of strategies leading to a personalized immunization without the need of expensive and complex ex vivo manipulation of patients’ PBMCs. Here, we will review and compare novel approaches on nanoparticle-based-targeted vaccine platforms, evaluating their molecular mechanisms of action, their translation ability, their efficacy, and their cost.

AB - Only a small fraction of any administered drug, including a vaccine, reaches its intended target tissue or cells. Homing vaccines to antigen-presenting cells (APC), where they can do their magic, has been the focus of attention for several decades. Since they are equipped with proper co-stimulatory signals, only professional APC are able to correctly process antigens and stimulate T and B cells to mount specific immune responses. With advances in the fields of modern immunology and nanotechnology, the new vaccine delivery platforms are emerging. APC-targeted vaccine delivery is required to elicit protective immunity, to reduce manufacturing costs, to minimize unanticipated effects of vaccines caused by off-target effects (thus reducing immunosuppressive mechanisms and toxicity), and to dramatically increase immunization efficacy. Indeed, in vivo targeting of APCs may represent the best hope for the generation of strategies leading to a personalized immunization without the need of expensive and complex ex vivo manipulation of patients’ PBMCs. Here, we will review and compare novel approaches on nanoparticle-based-targeted vaccine platforms, evaluating their molecular mechanisms of action, their translation ability, their efficacy, and their cost.

UR - http://www.scopus.com/inward/record.url?scp=84957685305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957685305&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-00978-0_21

DO - 10.1007/978-3-319-00978-0_21

M3 - Chapter

AN - SCOPUS:84957685305

SN - 9783319009780

SN - 9783319009773

SP - 753

EP - 766

BT - Molecular Vaccines: From Prophylaxis to Therapy - Volume 2

PB - Springer International Publishing

ER -